Introduction {#Sec1}
============

Transurethral resection of the prostate (TURP) remains first line treatment for surgical management of lower urinary tract symptoms (LUTS) secondary to bladder outlet obstruction (BOO) caused by BPH in small and middle size glands \[[@CR1], [@CR2]\]. For prostates \> 70 to 80 cc, the EAU guidelines recommend open prostatectomy or laser enucleation. Published studies report that TURP is associated with higher complication rates when performed in larger glands, in particular regarding blood transfusion and TUR syndrome \[[@CR3]\]. We have carried out standardized monopolar TURP using a pressure-controlled suprapubic suction device safely and effectively in glands up to 200 cc. This study's objective was to assess perioperative complications and long-term patient outcomes after monopolar low-pressure TUR-P in patients with glands \< 70 cc vs. glands \> 70 cc.

Materials and methods {#Sec2}
=====================

Study design and patients {#Sec3}
-------------------------

Our study was approved by the University of Freiburg Ethics Committee and performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

The design of the study is retrospective with prospective long-term evaluation of available patients presenting for long-term follow-up after invitation. We identified patients who underwent transurethral resection of the prostate after 1/2009 (the beginning of electronic patient charts in our department) by reviewing our charts retrospectively. Until 2014 no laser treatment was performed in our clinic. Open prostatectomy was discussed with patients with large glands \> 100 cc but most patients underwent transurethral resection after informed consent.

Sample size calculation {#Sec4}
-----------------------

Ten patients with prostate volume \< 70 cc (group 1) and 10 with prostate volume \> 70 cc (group 2) were reviewed initially. Based on those patients, we did a power calculation for a non-inferiority study, with the percentage of IPSS-improvement as primary outcome and a 15% non-inferiority-margin, resulting in a sample size of 69 patients per group to yield 80% power.

Consequently, patients with initial prostate size \< 70 cc as measured by transrectal sonography and those with bigger glands were identified and a invitation letter was sent to invite them for a long-term follow-up visit and possible inclusion in the study. Interested patients presented for a follow-up visit. At follow-up they gave informed consent to be included in the study. Exclusion criteria for the study were known prostate cancer before the TUR-P and no available long-term follow-up or informed consent. Patients with incidental carcinoma in the resected material remained in the study. Patients with a preoperatively indwelling catheter were included for our assessment of subjective parameters and complications, but were excluded from the *Q*~max~ and PVR evaluations.

The study was closed when the calculated sample size was reached.

Surgical technique {#Sec5}
------------------

All surgeons are experienced board-certified surgeons or advanced residents under the supervision of board-certified surgeons.

Monopolar TURP is performed in highly standardized fashion in dorsal lithotomy position under general or spinal anesthesia. After the cystoscopic exclusion of bladder tumors, the bladder is filled with purisole (mannitol 5% solution in 3000 ml bags). A specially designed "flow controller" trocar 18 Fr (Olympus, Hamburg, Germany, first described by Korth in 1989 \[[@CR4], [@CR5]\]) is placed suprapubically and connected to a suction pump to maintain stable low-pressure conditions of irrigation fluid (about 14--18 cmH~2~O) (Fig. [1](#Fig1){ref-type="fig"}). TURP is then performed with a resectoscope (Olympus, 24 Fr) with one inflow channel. The instrument itself is not a continuous flow instrument but due to the permanent outflow via the suprapubic trocar continuous irrigation is possible. At the end of the procedure, the suprapubic trocar is removed and the puncture site is coagulated to avoid bleeding. A transurethral foley catheter is put in place and continuous irrigation maintained until the urine is clear.Fig. 1**a** Scheme of equipment. The suprapubic trocar is connected to a suction hose and pump. **b** Suprapubic suction trocar. This shows the suprapubic suction trocar directly after insertion into the previously filled bladder. The jet of irrigation fluid confirms the correct placement in the bladder. **c** Suprapubic suction trocar 2. The inner sheath of the suction trocar is placed and connected to a suction hose in order to maintain constant low-pressure conditions of irrigation fluid

Assessment {#Sec6}
----------

Baseline data at the time of surgery were collected including age, BMI, ASA \[[@CR6]\], PSA, prostate size (measured by transrectal ultrasound), IPSS, QoL, ICIQ, IIEF, PVR, and the *Q*~max~ and Charlson comorbidity indices \[[@CR7]\]. Perioperative data included resection weight, histologic results, length of catheterization and complications including transfusion rates, TUR syndrome as mentioned in the patient chart, and complications attributable to the suprapubic puncture. Functional outcomes were monitored at the latest available follow-up.

Early complications during the first 30 days after the surgery and late complications such as surgical procedures for recurrent adenoma, stricture or bladder neck obstruction were assessed. Complications are reported according to the Clavien classification modified for TURP \[[@CR7]\].

Statistics {#Sec7}
----------

Changes from baseline for IPSS, QoL, *Q*~max~, PVR, etc. compared to the latest available follow-up time and differences between the two groups were calculated using a Student's two-tailed *t* test. Statistical significance was defined as *p* \< 0.05. Statistics were performed using IBM SPSS Statistics 22.

Results {#Sec8}
=======

Patient characteristics {#Sec9}
-----------------------

Between 1/2014 and 9/2015, a total of 139 patients followed the invitation for a long-term follow-up and agreed to be enrolled in the study, of whom 69 and 70 had initial prostate size \< 70 and \> 70 cc, respectively. Patient characteristics are shown in Table [1](#Tab1){ref-type="table"}. Six and 14 patients in group 1 and 2 had an indwelling catheter prior to TURP, respectively. 12 patients in each group were on ASS therapy, which was not interrupted for the intervention. 6 vs. 5 were on warfarin therapy, which we bridged with low molecular heparin for the intervention.Table 1Patient characteristicsSmall prostates (\< 70 cc)\
*N* = 69Large prostates (\> 70 cc)\
*N* = 70*p* valueMeanMedianSDRangeMeanMedianSDRangeAge (years)67.3686.3050--7969.4706.355--870.052BMI27.0626.723.1920.76--37.3726.7726.623.6919.57--37.030.631ASA2211--322130.228CCI0.7010--40.801.30--60.808Prostate Volume (cc)475012.815--65100.297.523.170--1630PSA (ng/ml)3.262.492.720.26--14.817.896.236.121.05--31.700*ASA* American Society of Anesthesiologists physical status classification, *CCI* Charlson Comorbidity Index

Perioperative results {#Sec10}
---------------------

Procedure characteristics are shown in Table [2](#Tab2){ref-type="table"}. Operative time was significantly longer in group 2, but catheterization time and length of hospital stay did not differ between groups 1 and 2.Table 2Procedure characteristicsSmall prostates (\< 70 cc)Large prostates (\> 70 cc)*p* valueMeanMedianSDRangeMeanMedianSDRangeOperative time (min)55.44826.517--13582.675.537.732--2300.000Resection weight (g)24.872410.45--6054.355027.335--1700.000Catheterization time (h)48484.124--7250.1487.948--960.057Length of stay (h)78.6723148--28878.57217.348--1680.982

Functional results at long-term follow-up {#Sec11}
-----------------------------------------

Mean follow-up was 57 vs. 56 months for group 1 and 2, respectively.

Paired outcome measurements for our functional results are shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. We observed a highly significant improvement from baseline to follow-up in both groups regarding all the tested items. There was no significant difference between the two groups.Table 3Paired outcome measurements subjectiveSmall prostates (\< 70 cc)Large prostates (\> 70 cc)IPSS *N*6657 Follow-up months5556 BL, mean (SD)19.8(7.5)17.2 (8) FU, mean (SD)7.26 (5.86)6.22 (6.29) Δ, mean (SD)− 13.00 (7.68)− 11.07 (932) Relative Δ %, mean− 62.8755.98 *p* value absolute Δ0.210 *p* value relative Δ0.287IPSS QoL *N*6565 Follow-up months5756 BL, mean (SD)4.01 (1.38)3.54 (1.39) FU, mean (SD)1.42 (1.29)1.09 (0.99) Δ, mean (SD)− 2.78 (1.85)− 2.48 (1.66) Relative Δ %, mean− 64.41− 63.80 *p* value absolute Δ0.359 *p* value relative Δ0.927ICIQ *N*4545 Follow-up months5854 BL, mean (SD)4.33 (4.59)4.25 (5.02) FU, mean (SD)2.17 (3.65)1.58 (3.39) Δ, mean (SD)− 1.99 (4.74)− 1.91 (4.43) Relative Δ %, mean---- *p* value absolute Δ0.897 *p* value relative Δ--The difference of the *N* is explained by the fact that not all patients provided all the answers in the questionnaires. Patients with incomplete questionnaires were not included in the analysis of subjective outcomes*BL* base line value, *FU* follow-up value, *Δ* absolute difference FU − BL, *Relative Δ* percentage improvement Table 4Paired outcome measurements objectiveSmall prostates (\< 70 cc)Large prostates (\> 70 cc)*Q* ~max~*N*5053 Follow-up months5355 BL, mean (SD)11.43 ml/s (5.42)11.52 ml/s (5.23) FU, mean (SD)19.46 ml/s (11.02)22.11 ml/s (10.79) Δ, mean (SD)9.8 ml/s (10.45)10.84 ml/s (11.16) Relative Δ, mean139.20%129.77 *p* value absolute Δ0.694 *p* value relative Δ0.850PVR *N*5957 Follow-up months5756 BL, mean (SD)109.12 ml (77.08)151.86 ml (167.30) FU, mean (SD)34.84 ml (40.29)25.98 ml (56.66) Δ, mean (SD)− 70.56 ml (79.86)− 122.42 ml (164.97) Relative Δ, mean− 58.35%− 62.53% *p* value absolute Δ0.099 *p* value relative Δ0.801The difference of the *N* is explained by the fact that not all patients provided all the answers in the questionnaires. Patients with incomplete questionnaires were not included in the analysis of subjective outcomes*BL* base line value, *FU* follow-up value, *Δ* absolute difference FU − BL, *Relative Δ* percentage improvement

Complications {#Sec12}
-------------

Short-term, long-term, and overall complications are illustrated in Table [5](#Tab5){ref-type="table"}; specific complications are shown in Table [6](#Tab6){ref-type="table"}.Table 5ComplicationsSmall prostates (\< 70 cc)\
*N* = 69Large prostates (\> 70 cc)\
*N* = 70Short term complications Clavien 121 (30.43%)22 (31.88%) Clavien 22 (2.90%)9 (13.04%) Clavien 3a13 (18.84%)7 (10.14%) Clavien 3b8 (11.59%)11 (15.94%) Clavien 400 Clavien 50Long-term complications Clavien 100 Clavien 200 Clavien 3a00 Clavien 3b8 ((11.59%)5 (7.25%) Clavien 400 Clavien 500Overall Clavien 122 (31.88%)23 (33.33%) Clavien 23 (4.35%)10 (14.49%) Clavien 3a10 (14.49%)5 (7.25%) Clavien 3b13 (18.84%)17 (24.64%) Clavien 400 Clavien 500The complications were attributed to the Clavien score modified for TUR-P (citation see manuscript) Table 6Complications detailedSmall prostates (\< 70 cc)Large prostates (\> 70 cc)*p*Short-term complications *N*6970 Transient hematuria46 (67%)46 (67%)0.906 Bleeding requiring surgical revision8 (11.6%)11 (15.7%)0.483 Bleeding requiring blood transfusions0 (0%)2 (2.9%)0.160 Failed voiding trial4 (5.8%)3 (4.3%)0.442 Positive urine culture postoperative2 (2.9%)9 (12.9%)0.030\* Fever1 (1.4%)2 (2.9%)0.571 Urosepsis0 (0%)0 (0%)-- TUR-syndrome0 (0%)1 (1.4%)0.323 Pulmonary thromboembolism0 (0%)0 (0%)-- Myocardial infarction0 (0%)0 (0)-- Death0 (0%)0 (0%)--Long-term complications Follow-up months5756 Bladder neck contracture4 (5.9%)1 (1.4%)0.169 Urethral stricture5 (7.2%)4 (5.8%)0.733 Residual/recurrent adenoma needing surgical treatment1 (1.4%)3 (4.3%)0.314Differences between the two groups were calculated using a Student's two-tailed*t* test.\*Statistical significance was defined as*p* \< 0.05

The most frequent short-term complication (first 30 days postoperative) was transient hematuria, self-limiting in most patients. Surgical revision due to prolonged bleeding was needed in 8 (11.6%) vs. 11 (15.7%) patients in group 1 vs. 2, respectively (*p* = 0.483). Blood transfusions were necessary in 0 vs. 2 (2.9%) patients (*p* = 0.160).

One patient in group 2 was diagnosed as having TUR syndrome. One patient in group 2 suffered a myocardial infarction during the first 30 days after surgery.

A positive urine culture during the first 3 days after surgery was significantly more frequent in group 2 (2 vs. 9 patients, *p* = 0.030\*), but did not result in higher rates of fever or sepsis.

Regarding long-term complications, we noted a tendency for more bladder neck contractures in group 1, but more recurrent adenomas in group 2. Strictures revealed no difference.

No patient reported new onset incontinence related to the surgery.

Patient satisfaction {#Sec13}
--------------------

Patient satisfaction was measured via the Freiburg Index for Patient Satisfaction \[[@CR8], [@CR9]\]; patients in both groups rated the surgical intervention as "very good" to "good" (1.78 vs. 1.67, *p* = 0.6).

Pain and analgesic consumption {#Sec14}
------------------------------

Pain and analgesic consumption were assessed using the visual analogue scale (VAS) and the cumulative analgesic consumption score \[[@CR10]\] for day 0, 1, and 2 after surgery (Table [7](#Tab7){ref-type="table"}). This score allows a more objective assessment of perioperative pain than the subjective visual analogue scale. No difference was observed in the mean VAS score; group 2's analgesic consumption was slightly lower.Table 7Analgesic consumptionSmall prostates (\< 70 cc)Large prostates (\> 70 cc)*p* valueDay 0 VAS1.361.070.332 CACS6.325.370.033Day 1 VAS0.420.390.847 CACS0.670.500.434Day 2 VAS0.360.310.789 CACS0.680.530.543Total VAS0.860.700.464 CACS7.716.130.018Pain and analgesic consumption were assessed using the visual analogue scale (VAS) and the cumulative analgesic consumption score for day 0, 1, and 2 after surgery. This score allows a more objective assessment of perioperative pain than the subjective visual analogue scale and is explained in detail in the article cited in the manuscript*VAS* visual analogue scale, *CACS* cumulative analgesic consumption score

Discussion {#Sec15}
==========

TURP is still the recommended first line treatment for BPH with gland sizes between 30 and 70--80 ml \[[@CR1]\]. It is a safe and effective treatment option and improves relevant patient outcomes significantly: a meta-analysis revealed an IPSS reduction of 70%, *Q*~max~ + 162%, and PVR urine − 77% \[[@CR11]\]. However, long operating times with hypo-osmolar irrigation fluid as needed for monopolar TURP can raise the risk for TUR-syndrome \[[@CR12]\] or bleeding \[[@CR13]\].

Alternatives like open prostatectomy, holmium laser enucleation or laser vaporization of the prostate are, therefore, recommended for larger glands. Open prostatectomy is an effective alternative, but due to its safety profile (blood transfusion rates 7--14%), it is considered an invasive option \[[@CR13], [@CR14]\]. Holmium laser enucleation is an accepted alternative for treating obstructing glands \> 70 to 80 cc, but requires special equipment and a high-power laser \[[@CR15]\].

The procedure we describe here is not new. Korth described this technique in 1989, and Heidler published an RCT comparing the Korth trocar with another suprapubic drainage system and the well-known Iglesias continuous-flow resectoscope \[[@CR4], [@CR16]\]. They showed that intravesical pressure is diminished with the trocar, and that this helps to keep plasma sodium concentrations stable. However, this technique has not gained acceptance and is rarely used. We identified no study applying this technique for prostates \> 70 g and believe that we demonstrate hereby a means of overcoming the irrigation-related problems in monopolar TUR-P without requiring invasive open prostatectomy or expensive new equipment.

Study design {#Sec16}
------------

To adequately investigate prostate size as an influencing factor, we decided to compare small prostates vs. large prostates, all operated with the same technique. Randomization is not possible with this design. We chose 70 cc as the cut-off in accordance with other publications \[[@CR14], [@CR17]\]. Despite our having a mixed retrospective--prospective study design, our study's patients exhibited no significant differences in baseline characteristics like age and comorbidities. Their follow-up periods were also the same.

Procedure characteristics {#Sec17}
-------------------------

As expected, group 2's operating time was longer. It has been postulated that resection times over 90 min enhance the risk for irrigation-related complications \[[@CR18]\]. The mean resection time of 82 min for the bigger glands in this series is still below this (virtual) limit. Nevertheless, even patients requiring longer operation times experienced no TUR syndrome or excessive bleeding. The resection weight in group 2 is lower than expected. The most probable explanation is a combination of imprecise sonographic measurement of prostate size, dehydration of resected material before weighing, and incomplete removal of adenoma.

Functional results {#Sec18}
------------------

Our patients' functional results regarding smaller and bigger prostates (IPSS, QoL, ICIQ, PVR, QoL) at long-term follow-up are the same and in line with other data on monopolar TUR-P \[[@CR11], [@CR19], [@CR20]\]. A limitation of our study is that we could not assess data at more time points sooner after the intervention.

Short-term complications {#Sec19}
------------------------

Our rates for failed voiding trials and blood transfusions correspond to those reported in the literature \[[@CR20], [@CR21]\].

Group 2 exhibited a significantly higher rate of positive urine cultures requiring antibiotic coverage, but no severe infectious problems were evident.

Bleeding {#Sec20}
--------

Bleeding was reported to be more likely with a resection time \> 90 min (7.3 vs. 0.9%) \[[@CR18]\].

We noted two blood transfusions in group 2 vs. 0 in group 1 (not significant in our series), but not significantly more bleeding scenarios requiring surgical intervention. Patients needing such revision were mainly patients with heparin bridging of warfarin therapy. Our bleeding percentages are still much lower than those reported in the literature.

TUR syndrome {#Sec21}
------------

Dilutional hyponatremia is a feared complication of monopolar transurethral resection with hypoosmolar irrigation fluid, resulting in neurologic and cardiologic symptoms. There is evidence that the incidence of developing TUR syndrome is significantly higher (2%) in patients whose resection time is \> 90 min compared to those whose resection time lasts under 90 min (0.7%) \[[@CR18]\]. In our series, only one TUR syndrome was diagnosed in group 2---thus demonstrating the suprapubic suction pump's effectiveness. As a limitation it must be stated that the postoperative course of TUR-P patients did only include measurement of serum sodium in cases of clinical suspicion of TUR syndrome.

It is noteworthy that we observed no complications related to the suprapubic trocar in this series.

Long-term complications {#Sec22}
-----------------------

We detected no statistical differences in the rate of reintervention because of bladder neck contracture, urethral stricture, or residual adenoma. The percentages presented here seem to be acceptable, especially when our long follow-up (nearly 5 years) is considered. However, the percentage of reinterventions was higher in the group with large glands and it could be possible that with longer follow-up and larger patient numbers this could become statistically significant.

This technique might appear outdated. It was first described by Korth and is based on even older publications recommending suprapubic suction devices to maintain low-pressure conditions in the bladder \[[@CR4], [@CR5], [@CR22]\]. As a consequence of the spread of industry-driven technological progress mandating alternatives such as laser techniques, many investigations have been conducted, although many of the more recent ones revealed no overwhelming advantages over TUR-P, merely non-inferiority \[[@CR20], [@CR21]\]. In our department we introduced HoLEP for bigger glands, and we now employ it in conjunction with almost every surgical BPH therapy regardless of the prostate volume.

However, we aimed to remind the urologic community of this effective, safe, and cheap alternative to standard treatment options for bigger prostates. We believe it is a potentially promising option in clinical settings where open prostatectomy seems overly invasive but where introducing HoLEP or other laser methods is too expensive. To the best of our knowledge, this is the first study to compare this low-pressure monopolar resection for patients with LUTS secondary to BPH with small vs. large prostatic volumes with such long follow-up.

The study is limited by its retrospective character. We cannot provide short-term functional results because not all our patients presented for follow-up at our department.

There is a risk of bias because some patients with worse outcomes might have refused to participate in the long-term follow-up. Postoperative blood counts are not available for all patients, because we require postoperative blood analyses only from patients presenting prolonged bleeding or suspected anemia.

Furthermore, some patients with bigger glands might have been operated on by more experienced surgeons, thus creating a performance bias. This study was powered for IPSS-improvement. The minimal differences in complications we observed here might have become statistically significant had we enrolled more patients.

No direct comparison has been made with patients treated by endoscopic enucleation or open simple prostatectomy.

Conclusion {#Sec23}
==========

In terms of safety and efficacy, the present modality of standardized monopolar TURP using suprapubic suction was non-inferior for prostates \> 70 cc compared to the same procedure for prostates \< 70 cc. These findings add new evidence on affordable surgical treatment options for large prostatic glands. However, this technique requires additional validation in larger cohorts and at other centers, and direct comparison to more recent laser ablative interventions.
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